ABO blood group system

ABO blood group system
InvictaHOG · Public domain · source
Name	ABO blood group system
First discovered	1900
Discovered by	Karl Landsteiner
Antigen	A and B antigens
Gene	ABO

ABO blood group system is a human blood classification system defined by the presence or absence of A and B antigens on erythrocyte surfaces and corresponding anti-A and anti-B antibodies in plasma. It is central to clinical transfusion practice, immunohematology, infectious disease research, and population genetics. The system's biochemical basis, genetic inheritance, and epidemiological patterns have been studied across diverse settings including Vienna, Chicago, Paris, London, and Tokyo.

Overview

The ABO system categorizes individuals into four principal phenotypes: A, B, AB, and O, determined by distinct antigenic profiles on red blood cells and reciprocal antibodies in serum. Foundational studies in Vienna and early 20th-century laboratories linked ABO typing to safe blood transfusion practices in hospitals such as Johns Hopkins Hospital, Guy's Hospital, and Massachusetts General Hospital. ABO phenotypes influence compatibilities used in protocols at institutions like the American Red Cross, National Health Service, and the World Health Organization. Blood group distributions are routinely reported in national registries such as the United States Census Bureau health datasets, the Brazilian Ministry of Health, and the Indian Council of Medical Research surveillance programs.

Genetics and Biochemistry

The ABO blood groups are encoded by the ABO gene on human chromosome 9, which produces glycosyltransferase enzymes that modify the H antigen precursor on erythrocyte membranes. Molecular characterization by researchers associated with institutions such as the Max Planck Society, Cold Spring Harbor Laboratory, and the National Institutes of Health clarified allele variants designated A1, A2, B, O (including subtypes like O1 and O2) and rarer cis-AB alleles identified in genetic studies involving populations sampled by the University of Oxford, Harvard University, and the University of Tokyo. Glycosyltransferase activity was elucidated through biochemical work at facilities including the Rockefeller University and Karolinska Institutet, demonstrating how nucleotide substitutions alter enzyme specificity and antigenic structure. The O allele commonly results from a frameshift mutation producing an inactive enzyme; this mutation was mapped by teams collaborating with the Sanger Centre and the Wellcome Trust. The H antigen dependency implicates the FUT1 gene, characterized in research supported by the European Molecular Biology Laboratory and the National Health and Medical Research Council of Australia.

Clinical Significance and Transfusion Medicine

ABO compatibility is the primary determinant of acute hemolytic transfusion reactions managed in centers such as Mayo Clinic, Cleveland Clinic, and Addenbrooke's Hospital. Mismatched transfusions precipitate complement-mediated hemolysis observed and treated in intensive care units at hospitals like St Thomas' Hospital and transplant centers including University College Hospital London and Massachusetts General Hospital. ABO typing underpins organ transplantation allocation coordinated through organizations such as the United Network for Organ Sharing and national registries in Spain, France, and Germany. Hemolytic disease of the fetus and newborn involving ABO incompatibility is studied in perinatal units at Karolinska University Hospital and Charité – Universitätsmedizin Berlin. Clinical assays for typing and crossmatching were standardized by bodies like the International Society of Blood Transfusion, the American Association of Blood Banks, and regulatory agencies including the Food and Drug Administration and the European Medicines Agency.

Population Distribution and Evolution

Global frequencies of ABO phenotypes show marked geographic variation: high O prevalence in populations sampled by anthropologists working with the Smithsonian Institution and the American Museum of Natural History in the Americas, elevated B frequencies in cohorts studied in Mongolia, China, and parts of Central Asia by research teams from Peking University and Mongolian Academy of Sciences, and diverse mixes across Europe documented by projects at the Max Planck Institute for Evolutionary Anthropology and the University of Cambridge. Evolutionary hypotheses linking ABO variation to selective pressures from pathogens have involved collaborations with groups at Institut Pasteur, London School of Hygiene & Tropical Medicine, and the Walter Reed Army Institute of Research, implicating agents such as Plasmodium falciparum, Helicobacter pylori, and various norovirus strains. Population genetics analyses using data from initiatives like the 1000 Genomes Project, the Human Genome Diversity Project, and regional biobanks at UK Biobank and the China Kadoorie Biobank model demographic history, migration, and balancing selection shaping ABO allele distributions.

History and Discovery

The discovery of ABO blood groups traces to the work of Karl Landsteiner in Vienna in 1900, with subsequent conceptual and practical developments by contemporaries in laboratories across Europe and North America. Early clinical applications emerged in hospitals such as The Middlesex Hospital and Bellevue Hospital, while Nobel recognition and scientific debate involved figures associated with institutions like the Royal Society and the Austrian Academy of Sciences. Later molecular breakthroughs were advanced by researchers affiliated to the University of Geneva, Princeton University, and the NIH, culminating in allele sequencing and enzyme assays performed at centers including the Sanger Institute and Institut Pasteur. The integration of ABO knowledge into transfusion services catalyzed the formation of national blood services exemplified by the Japanese Red Cross Society, the Italian Blood Donor Association, and the Red Cross Society of China.

Category:Blood